

**Fellow Publications/Presentations  
January through December 2020**

**Publications**

1. Patel BJ, **Barot SV**, Waldron M, Billings S, Vij A, Sekeres MA, Maciejewski JP, Carraway HE. Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria. *Leuk Lymphoma*. 2020 May;61(5):1242-1245. doi: 10.1080/10428194.2019.1706734. Epub 2019 Dec 28. PMID: 31885297.
2. Patel BJ, **Barot SV**, Kuzmanovic T, Kerr C, Przychodzen BP, Thota S, Lee S, Patel S, Radivoyevitch T, Lichtin A, Advani A, Kalaycio M, Sekeres MA, Carraway HE, Maciejewski JP. Distinctive and common features of moderate aplastic anaemia. *Br J Haematol*. 2020 Jun;189(5):967-975. doi: 10.1111/bjh.16460. Epub 2020 Jan 31. PMID: 32004386.
3. **Barot SV**, Patel BJ, Gerds AT. Patient-Reported Outcomes in Myelodysplastic Syndromes: the Move from Life Span to Health Span. *Curr Hematol Malig Rep*. 2020 Apr;15(2):149-154. doi: 10.1007/s11899-020-00562-9. PMID: 32048198.
4. Durer C, Durer S, Lee S, **Chakraborty R**, Malik MN, Rafea A, Zar MA, Kamal A, Rosko N, Samaras C, Valent J, Chaulagain C, Anwer F. Treatment of relapsed multiple myeloma: Evidence-based recommendations. *Blood Rev*. 2020 Jan;39:100616. doi: 10.1016/j.blre.2019.100616. Epub 2019 Aug 31. PMID: 31500848.
5. **Chakraborty R**, Majhail NS. Treatment and disease-related complications in multiple myeloma: Implications for survivorship. *Am J Hematol*. 2020 Jun;95(6):672-690. doi: 10.1002/ajh.25764. Epub 2020 Mar 13. PMID: 32086970; PMCID: PMC7217756.
6. **Chakraborty R**, Muchtar E, Gertz MA. Newer Therapies for Amyloid Cardiomyopathy. *Curr Heart Fail Rep*. 2016 Oct;13(5):237-246. doi: 10.1007/s11897-016-0300-1. PMID: 27497715.
7. **Chakraborty R**, Kapoor P, Ansell SM, Gertz MA. Ibrutinib for the treatment of Waldenström macroglobulinemia. *Expert Rev Hematol*. 2015 Oct;8(5):569-79. doi: 10.1586/17474086.2015.1061427. Epub 2015 Jul 2. PMID: 26138997.
8. **Chakraborty R**, Sidana S, Shah GL, Scordo M, Hamilton BK, Majhail NS. Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities. *Biol Blood Marrow Transplant*. 2019 May;25(5):e155-e162. doi: 10.1016/j.bbmt.2018.11.025. Epub 2018 Nov 28. PMID: 30500439; PMCID: PMC6511294.
9. Basali D, **Chakraborty R**, Rybicki L, Rosko N, Reed J, Karam M, Schlueter K, Dysert H, Kalaycio M, Valent J. Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma. *Br J Haematol*. 2020 Jun;189(6):1136-1140. doi: 10.1111/bjh.16454. Epub 2020 Feb 3. PMID: 32012228.
10. **Chakraborty R**, Bin Riaz I, Malik SU, Marneni N, Mejia Garcia A, Anwer F, Khorana AA, Rajkumar SV, Kumar S, Murad MH, Wang Z, Khan SU, Majhail NS. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite

thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis. *Cancer*. 2020 Apr 15;126(8):1640-1650. doi: 10.1002/cncr.32682. Epub 2020 Jan 8. PMID: 31913498; PMCID: PMC7453956.

11. **Chakraborty R**, Rybicki L, Nakashima MO, Dean RM, Faiman BM, Samaras CJ, Rosko N, Dysert H, Valent J, Anwer F. Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma. *Br J Haematol*. 2020 Jun;189(6):1074-1082. doi: 10.1111/bjh.16488. Epub 2020 Feb 28. PMID: 32108328.
12. Wongsangsak S, Kopel J, Behera TR, **Chakraborty R**, Ball S. Infection risk with carfilzomib in multiple myeloma: a systematic review and meta-analysis of randomised controlled trials. *Br J Haematol*. 2020 Jul;190(2):e95-e97. doi: 10.1111/bjh.16735. Epub 2020 May 13. PMID: 32400886.
13. Ball S, Behera TR, Anwer F, **Chakraborty R**. Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials. *Ann Hematol*. 2020 Jun;99(6):1265-1271. doi: 10.1007/s00277-020-04062-x. Epub 2020 May 7. PMID: 32382772.
14. Radakovich N, **Cortese M**, Nazha A. Acute myeloid leukemia and artificial intelligence, algorithms and new scores. *Best Pract Res Clin Haematol*. 2020 Sep;33(3):101192. doi: 10.1016/j.beha.2020.101192. Epub 2020 Jun 7. PMID: 33038981; PMCID: PMC7548395.
15. Socha DS, **DeSouza SI**, Flagg A, Sekeres M, Rogers HJ. Severe megaloblastic anemia: Vitamin deficiency and other causes. *Cleve Clin J Med*. 2020 Mar;87(3):153-164. doi: 10.3949/ccjm.87a.19072. PMID: 32127439.
16. **Fallah J**, Diaz-Montero CM, Rayman P, Wei W, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Dann P, Company D, Stephenson A, Campbell S, Haber G, Lee B, Mian O, Gilligan T, Garcia JA, Rini B, Ornstein MC, Grivas P. Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall Survival. *Clin Genitourin Cancer*. 2020 Dec;18(6):500-508. doi: 10.1016/j.clgc.2020.03.004. Epub 2020 Mar 19. PMID: 32340875.
17. Dutcher JP, Flippot R, **Fallah J**, Escudier B. On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment-Cytokines, Targeted Therapy, and Immunotherapy. *Am Soc Clin Oncol Educ Book*. 2020 Mar;40:1-18. doi: 10.1200/EDBK\_280817. PMID: 32243201.
18. Sheng IY, **Fallah J**, Gupta R, Li H, Allman K, Martin A, Barata P, Ornstein MC, Gilligan TD, Rini BI, Garcia JA. Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone. *Target Oncol*. 2020 Aug;15(4):477-483. doi: 10.1007/s11523-020-00734-w. PMID: 32661959.
19. Warraich Z, Tenneti P, Thai T, **Hubben A**, Amin H, McBride A, Warraich S, Hannan A, Warraich F, Majhail N, Kalaycio M, Anwer F. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review. *Biol Blood Marrow Transplant*. 2020 Mar;26(3):e55-e64. doi: 10.1016/j.bbmt.2019.09.022. Epub 2019 Sep 23. PMID: 31557532.

20. **Kishtagari A**, Levine RL, Viny AD. Driver mutations in acute myeloid leukemia. *Curr Opin Hematol*. 2020 Mar;27(2):49-57. doi: 10.1097/MOH.0000000000000567. PMID: 31972687.
21. Durrani J, Awada H, **Kishtagari A**, Visconte V, Kerr C, Adema V, Nagata Y, Kuzmanovic T, Hong S, Patel B, Nazha A, Lichtin A, Mukherjee S, Sauntharajah Y, Carraway H, Sekeres M, Maciejewski JP. Large granular lymphocytic leukemia coexists with myeloid clones and myelodysplastic syndrome. *Leukemia*. 2020 Mar;34(3):957-962. doi: 10.1038/s41375-019-0601-y. Epub 2019 Oct 17. PMID: 31624375.
22. **Kishtagari A**, Sekeres MA. Eat and be healthy: nutritional status in myelodysplastic syndromes. *Leuk Lymphoma*. 2020 Dec;61(12):2788-2789. doi: 10.1080/10428194.2020.1797015. Epub 2020 Jul 25. PMID: 32715818.
23. Awada H, Mahfouz RZ, **Kishtagari A**, Kuzmanovic T, Durrani J, Kerr CM, Patel BJ, Visconte V, Radivoyevitch T, Lichtin A, Carraway HE, Maciejewski JP, Sauntharajah Y. Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies. *Br J Haematol*. 2020 Mar;188(6):924-929. doi: 10.1111/bjh.16281. Epub 2019 Nov 17. PMID: 31736067; PMCID: PMC7154732.
24. **Kishtagari A**, Levine RL. The Role of Somatic Mutations in Acute Myeloid Leukemia Pathogenesis. *Cold Spring Harb Perspect Med*. 2020 May 12:a034975. doi: 10.1101/cshperspect.a034975. Epub ahead of print. PMID: 32398288.
25. Awada H, Mahfouz RZ, Durrani J, **Kishtagari A**, Jagadeesh D, Lichtin AE, Hill BT, Hamilton BK, Carraway HE, Nazha A, Majhail NS, Sobeks R, Visconte V, Kalaycio M, Sekeres MA, Maciejewski JP. Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation. *Br J Haematol*. 2020 Apr;189(2):318-322. doi: 10.1111/bjh.16336. Epub 2020 Jan 20. PMID: 31958160.
26. **Kunte S**, Abraham J, Montero AJ. Novel HER2-targeted therapies for HER2-positive metastatic breast cancer. *Cancer*. 2020 Oct 1;126(19):4278-4288. doi: 10.1002/cncr.33102. Epub 2020 Jul 28. PMID: 32721042.
27. **Kunte S**, Stevenson J. A Case of HLA-DRB1-MET Rearranged Lung Adenocarcinoma With Rapid Response to Crizotinib. *Clin Lung Cancer*. 2020 Jun 12:S1525-7304(20)30145-5. doi: 10.1016/j.clcc.2020.05.005. Epub ahead of print. PMID: 32654927.
28. Durer C, Durer S, **Lee S**, Chakraborty R, Malik MN, Rafae A, Zar MA, Kamal A, Rosko N, Samaras C, Valent J, Chaulagain C, Anwer F. Treatment of relapsed multiple myeloma: Evidence-based recommendations. *Blood Rev*. 2020 Jan;39:100616. doi: 10.1016/j.blre.2019.100616. Epub 2019 Aug 31. PMID: 31500848.
29. **Lemmon C**, Pennell NA. Use of adjuvant EGFR tyrosine kinase inhibitors in early stage *EGFR*-mutant non-small cell lung cancer: is the evidence strong enough? *J Thorac Dis*. 2020 Sep;12(9):5042-5045. doi: 10.21037/jtd-20-1817. PMID: 33145076; PMCID: PMC7578493.
30. **Nizam A**, Trump DL, Aragon-Ching JB. Characterization of Brain Metastases in Urothelial Cancers. *Clin Genitourin Cancer*. 2020 Dec;18(6):e679-e683. doi: 10.1016/j.clgc.2020.03.015. Epub 2020 Apr 7. PMID: 32359862.

31. **Nizam A**, Schindelheim JA, Ornstein MC. The role of active surveillance and cytoreductive nephrectomy in metastatic renal cell carcinoma. *Cancer Treat Res Commun*. 2020 Feb 22;23:100169. doi: 10.1016/j.ctarc.2020.100169. Epub ahead of print. PMID: 32126518.
32. Khorrami M, Prasanna P, Gupta A, **Patil P**, Velu PD, Thawani R, Corredor G, Alilou M, Bera K, Fu P, Feldman M, Velcheti V, Madabhushi A. Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung Cancer. *Cancer Immunol Res*. 2020 Jan;8(1):108-119. doi: 10.1158/2326-6066.CIR-19-0476. Epub 2019 Nov 12. PMID: 31719058; PMCID: PMC7718609.
33. Zagouras A, **Patil PD**, Yogi-Morren D, Pennell NA. Cases from the Immune-Related Adverse Event Tumor Board: Diagnosis and Management of Immune Checkpoint Blockade-Induced Diabetes. *Oncologist*. 2020 Nov;25(11):921-924. doi: 10.1634/theoncologist.2019-0806. Epub 2020 Jul 7. PMID: 32564463; PMCID: PMC7648337.
34. Vaidya P, Bera K, **Patil PD**, Gupta A, Jain P, Alilou M, Khorrami M, Velcheti V, Madabhushi A. Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade. *J Immunother Cancer*. 2020 Oct;8(2):e001343. doi: 10.1136/jitc-2020-001343. PMID: 33051342; PMCID: PMC7555103.
35. Khorrami M, Bera K, Leo P, Vaidya P, **Patil P**, Thawani R, Velu P, Rajiah P, Alilou M, Choi H, Feldman MD, Gilkeson RC, Linden P, Fu P, Pass H, Velcheti V, Madabhushi A. Stable and discriminating radiomic predictor of recurrence in early stage non-small cell lung cancer: Multi-site study. *Lung Cancer*. 2020 Apr;142:90-97. doi: 10.1016/j.lungcan.2020.02.018. Epub 2020 Feb 26. PMID: 32120229; PMCID: PMC7141152.
36. Khanna S, Palackdharry S, **Roof L**, Wicker CA, Mark J, Zhu Z, Jandorav R, Molinolo A, Takiar V, Wise-Draper TM. Determining the molecular landscape and impact on prognosis in HPV-associated head and neck cancer. *Cancers Head Neck*. 2020 Sep 9;5:11. doi: 10.1186/s41199-020-00058-2. PMID: 32944296; PMCID: PMC7487583.
37. Mehta N, **Sadaps M**, Patil DT, Bhatt A. Metastatic Renal Cell Carcinoma Found in the Stomach and Duodenum. *ACG Case Rep J*. 2020 Jan 17;7(1):e00307. doi: 10.14309/crj.0000000000000307. PMID: 32309500; PMCID: PMC7145171.
38. Mehta N, Abushahin A, **Sadaps M**, Alomari M, Vargo J, Patil D, Lopez R, Kalady M, Delaney CP, Gorgun E, Church J, Saito Y, Burke CA, Bhatt A. Recurrence with malignancy after endoscopic resection of large colon polyps with high-grade dysplasia: incidence and risk factors. *Surg Endosc*. 2020 May 29. doi: 10.1007/s00464-020-07660-y. Epub ahead of print. PMID: 32472496.
39. Mehta N, Abushahin A, **Sadaps M**, Alomari M, Vargo J, Patil D, Lopez R, Kalady M, Delaney CP, Gorgun E, Church J, Saito Y, Burke CA, Bhatt A. Recurrence with malignancy after endoscopic resection of large colon polyps with high-grade dysplasia: incidence and risk factors. *Surg Endosc*. 2020 May 29. doi: 10.1007/s00464-020-07660-y. Epub ahead of print. PMID: 32472496.

40. **Sheng IY**, Wei W, Chen Y, Gilligan T, Ornstein M, Rini B, Garcia J. Implications of the US Preventative Services Task Force Recommendations on Prostate Cancer Stage Migration. *Clin Genitourin Cancer*. 2020 July. PMID 32800474
41. **Sheng IY**, Fallah J, Gupta R, Li H, Allman K, Martin A, Barata P, Ornstein M, Gilligan T, Rini B, Garcia J. Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone. *Targ Oncol*. 2020 July. PMID 32661959
42. **Sheng IY**, Ornstein M. Ipilimumab and Nivolumab as first-line treatment for patients with renal cell carcinoma: the evidence to date. *Cancer management and Research*. 2020 May; 2020(12): 4871-4881. PMID 32606975
43. **Sheng IY**, Diaz-Montero CM, Rayman P, Wei W, Finke JH, Kim JS, Pavicic PG, Lamenza M, Company D, Stephenson A, Campbell S, Haber G, Lee B, Mian O, Gilligan TD, Rini BI, Garcia JA, Grivas P, Ornstein MC. Blood Myeloid Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio (NLR) and Overall Survival (OS) in Metastatic Urothelial Carcinoma. *Targ Oncol*. 2020 Apr;15(2):211-220. PMID 32207064
44. Gupta R, **Sheng IY**, Barata PC, Garcia JA. Non-metastatic castration-resistant prostate cancer: current status and future directions. *Expert Rev Anticancer Ther*. 2020 Jun;20(6):513-522. doi: 10.1080/14737140.2020.1772759. Epub 2020 Jun 7. PMID: 32508166.
45. Conic RRZ, Knackstedt R, **Sussman TA**, Rambhia S, Damiani G, Funchain P, Ko J, Gastman BR. Utilization and impact of immunotherapy in stage IV melanoma using the National Cancer Database. *Melanoma Res*. 2020 Aug;30(4):376-385. doi: 10.1097/CMR.0000000000000672. PMID: 32404731.
46. **Sussman TA**, Funchain P, Singh A. Clinical Trials in Metastatic Uveal Melanoma: Current Status. *Ocul Oncol Pathol*. 2020 Dec;6(6):381-387. doi: 10.1159/000508383. Epub 2020 Sep 10. PMID: 33447587; PMCID: PMC7772871.
47. **Sussman TA**, Funchain P, Singh A. Clinical Trials in Metastatic Uveal Melanoma: Current Status. *Ocul Oncol Pathol*. 2020 Dec;6(6):381-387. doi: 10.1159/000508383. Epub 2020 Sep 10. PMID: 33447587; PMCID: PMC7772871.
48. **Wright MD**, Abraham MJ. Preclinical discovery and development of abemaciclib used to treat breast cancer. *Expert Opin Drug Discov*. 2020 Dec 7. doi: 10.1080/17460441.2021.1853097. Epub ahead of print. PMID: 33280445.

### **Poster Presentations/Abstracts**

1. **Cortese M**, Wei W, Cerdna S, et. al. A Multi-Center Analysis of the Impact of Dose Level of R-EPOCH on Outcomes of Patients with Double/Triple-Hit B-Cell Lymphoma. ASH 2020 Virtual Meeting. December 2020 (Poster)
2. **Cortese M**, Wei W, Cerdna S, et. al. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas) – Results from Retrospective/Observational Studies. ASH 2020 Virtual Meeting. December 2020 (Poster)

3. **Fallah J**, Chaudhary R, Rogers L, Wei W, Brewer C, Peereboom D, Ahluwalia M. Clinical outcomes of the combination of bevacizumab and ttfelds in patients with recurrent glioblastoma: Results of a phase II clinical trial. 2020, ASCO20 Virtual Scientific Program, May 2020 (Poster)
4. **Hubben A**, Rybicki L, Ricci K, et. al. Hematopoietic Progenitor Cell Mobilization and Collection for Autologous Hematopoietic Cell Transplantation in AL Amyloidosis: A Single Center Experience. ASH 2020 Virtual Meeting. December 2020. (Poster)
5. **Kunte S**, Rybicki L, Viswabandya A, et. al. Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience. ASH 2020 Virtual Meeting. December 2020 (Poster)
6. **Lemmon C**, Videtic G, Murthy S, et al. A phase I safety and feasibility study of neoadjuvant chemoradiation plus pembrolizumab followed by consolidation pembrolizumab in resectable stage IIIA non-small cell lung cancer. ASCO 2020 Virtual Scientific Program, May, 2020 (Poster)
7. **Nair K**, et. al. Outcomes of appendiceal adenocarcinomas compared to right and left-sided colorectal adenocarcinomas: An analysis from the National Cancer Database (NCDB). Gastrointestinal Cancers Symposium. January 2020. (Poster)
8. **Sadaps M**, et. al. Tumor size and the risk for lymph node metastases in T1 esophageal adenocarcinoma. Gastrointestinal Cancers Symposium. January 2020. (Poster)
9. **Sadaps M**, et. al. Socioeconomic disparities in patients with esophageal cancer at time of diagnosis: a national cancer data base analysis. AACR Annual Meeting. April 2020 (Poster)
10. **Sheng IY**, et. al. Genitourinary oncology referral patterns to the cancer associated thrombosis clinic: The Cleveland Clinic experience. Genitourinary Cancer Symposium. February 2020. (Poster)
11. **Sheng IY**, et. al. PSA Pattern Changes Predict Progression in Patients with Metastatic Castrate Sensitive Prostate Cancer (mCSPC) Treated with Abiraterone and Prednisone (AA/P). GU-ASCO 2020, San Francisco CA, February 2020. (Poster)
12. **Sheng IY**, Fallah J, Gupta R, Li H, Allman KD, Martin A, Barata PC, Ornstein MC, Gilligan TD, Rini BI, Garcia JA. The association between PSA pattern changes and progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with abiraterone and prednisone (AA/P). GU-ASCO 2020, San Francisco CA, February 2020. (Poster)
13. **Sheng IY**, et al. Thromboembolism in patients with bladder cancer treated with checkpoint inhibitors (CPIs). May 2020 (Poster)
14. **Sheng IY**, Gupta S, Reddy C, et. al. Thromboembolism in Patients with Advanced Renal Cell Carcinoma Treated with Immunotherapy. ASH 2020 Virtual Meeting. December 2020 (Oral)

15. **Sussman T**, et. al. Venous thromboembolism (VTE) in melanoma patients (pts) on immunotherapy (IO). ASCO-SITC Clinical Immuno-Oncology Symposium. February 2020 (Poster)
16. **Sussman TA**, Wei W, Hobbs B, Ni Y, Arbesman J, Ko J, Gastman B, Funchain P. A Phase II trial of nivolumab in Combination with talazoparib in unresectable or metastatic melanoma patients with mutations in BRCA or BRCAness. American Society of Clinical Oncology 2020 Annual Meeting; Abstr. TPS10082; May 30, 2020. (Poster)